---
title: "First-In-Human Readiness Guide for Early-stage Biotechs"
description: "First-in-Human (FIH) is not the finish line of preclinical work, it's the foundation everything else builds on. The dose you select, the manufacturing process you lock in, and the operational setup you put in place now will decide whether your path to the clinic stays efficient and credible, or turns into delay and rework. This guide walks through the four areas that determine FIH readiness, and what to get right before you file."
url: https://qbdgroup.com/en/downloads/first-in-human-readiness-guide-early-stage-biotechs
type: "White paper"
language: en
published: 2026-08-12
author: "Angeles Escartí-Nebot"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"First-In-Human Readiness Guide for Early-stage Biotechs\", https://qbdgroup.com/en/downloads/first-in-human-readiness-guide-early-stage-biotechs"
---
# First-In-Human Readiness Guide for Early-stage Biotechs
> First-in-Human (FIH) is not the finish line of preclinical work, it's the foundation everything else builds on. The dose you select, the manufacturing process you lock in, and the operational setup you put in place now will decide whether your path to the clinic stays efficient and credible, or turns into delay and rework. This guide walks through the four areas that determine FIH readiness, and what to get right before you file.

<!-- subtitle: A Practical Framework for Getting Your Program to First-in-Human -->

First-in-Human (FIH) is not the finish line of preclinical work, it's the foundation everything else builds on. The dose you select, the manufacturing process you lock in, and the operational setup you put in place now will decide whether your path to the clinic stays efficient and credible, or turns into delay and rework. This guide walks through the four areas that determine FIH readiness, and what to get right before you file.

## About This White Paper

Most FIH delays aren't caused by bad science. They're caused by **fragmented decisions**: a nonclinical program designed without the intended clinical use in mind, a manufacturing process that changes without a comparability plan, a regulatory pathway chosen without checking what evidence it actually demands, a clinical operations setup improvised once the CTA is already filed.

Written by Angeles Escartí-Nebot, Global Head Regulatory Affairs at QbD Group, this guide sets out a **practical framework** across four areas that determine whether a development program is ready for First-in-Human and positioned for smooth progression toward Marketing Authorisation:

- Development Strategy and Regulatory Pathway
- Non-clinical Package Readiness
- CMC and Manufacturing Readiness
- Clinical Trial Application and Governance

For each area, you'll find the key decisions to make and when to make them, the gaps that most often delay or jeopardize CTA approval, what a well-prepared program looks like, and practical tips you can apply directly to your own program.

## Key Takeaways

- **Define your legal basis and TPP before nonclinical or CMC work begins.** These decisions determine the entire evidence package that follows.

- **In vivo animal studies are no longer the default.** FDA, MHRA, and EMA are shifting toward risk-based, weight-of-evidence assessments, provided the science justifies it.

- **CMC readiness for FIH means control and patient safety readiness, not commercial readiness.** Specifications, CQAs, and the stability program need to be locked in well before CTA submission.

- **Treat regulatory interaction as a strategic tool, not a formality.** Early scientific advice costs far less than a rejected or delayed CTA.

- **Four operational pillars need to be in place before dosing starts.** Sponsor governance, site readiness, trial design, and safety monitoring all need real ownership, not improvisation.

- **A successful CTA filing is not the goal; it is the result of a development program that is ready for FIH.** The practices that prepare a program for FIH are the same ones that support a smoother Marketing Authorisation path.
---
Source: https://qbdgroup.com/en/downloads/first-in-human-readiness-guide-early-stage-biotechs — © QbD Group. Quote freely with attribution and a link back.